| 2024 | | A Randomized, Multi-Center, Open Label Study to Compare the Safety and Efficacy between Afatinib Monotherapy and Combination Therapy with HAD-B1 for the Locally Advanced or Metastatic NSCLC Patients with EGFR Mutations | 이현우 |
| 2024 | | An epidermal growth factor receptor-targeting immunotoxin based on IgG shows potent antitumor activity against head and neck cancer | 김철호, 이복순, 이윤상 |
| 2024 | | Deep learning-based analysis of EGFR mutation prevalence in lung adenocarcinoma H&E whole slide images | 노진, 허재성 |
| 2024 | | Deep learning–radiomics integrated noninvasive detection of epidermal growth factor receptor mutations in non-small cell lung cancer patients | 김철호, 노진, 유슬기, 허재성 |
| 2024 | | Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study | 강석윤, 고영화, 김태환, 신승수, 안미선, 이현우, 최용원, 최진혁 |
| 2018 | | Diffusion-Weighted Imaging of Brain Metastasis from Lung Cancer: Correlation of MRI Parameters with the Histologic Type and Gene Mutation Status | 정우상 |
| 2018 | | EGFR Exon 19 Deletion is Associated With Favorable Overall Survival After First-line Gefitinib Therapy in Advanced Non-Small Cell Lung Cancer Patients | 강석윤, 고영화, 박준성, 신승수, 이현우, 정성현, 최용원, 최진혁, 한재호 |
| 2018 | | Identifying candidates for gamma knife radiosurgery among elderly patients with brain metastases | 김세혁, 노태훈, 유남규, 정동환 |
| 2023 | | Immune profiles according to EGFR mutant subtypes and correlation with PD-1/PD-L1 inhibitor therapies in lung adenocarcinoma | 고영화, 박범희, 이현우, 한재호, 함석진 |
| 2019 | | Interferon-induced transmembrane protein 1-mediated EGFR/SOX2 signaling axis is essential for progression of non-small cell lung cancer | 고영화 |
| 2024 | | Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset | 최진혁 |
| 2021 | | Neurofibromin deficiency causes epidermal growth factor receptor upregulation through the activation of Ras/ERK/SP1 signaling pathway in neurofibromatosis type 1-associated malignant peripheral nerve sheet tumor | 김정현, 박건후, 박은국, 이창근, 정선용 |
| 2024 | | Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study | 이현우 |
| 2020 | | Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09) | 안미선 |
| 2018 | | Recapitulation of pharmacogenomic data reveals that invalidation of SULF2 enhance sorafenib susceptibility in liver cancer | 김혁훈, 왕희정, 우현구, 윤사라 |
| 2022 | | The efficacy of EGFR-tyrosine kinase inhibitor in non-small cell lung cancer patients with synchronous brain metastasis: a real-world study | 강석윤, 김세혁, 노오규, 노태훈, 신승수, 안미선, 오영택, 이현우, 최용원, 최진혁 |
| 2023 | | Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial | 최진혁 |
